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MICROECONOMIC SURPLUS OR CONVENIENCE IN HEALTH CARE: APPLIED
ECONOMIC THEORY IN HEALTH CARE IN THREE EUROPEAN COUNTRIES
Walzer S1, Nuijten M2, Wiesner C3
1Market Access & Pricing Strategy UG (h.b.), Weil am Rhein, Germany, 2Ars Accessus Medica,
Amsterdam (Jisp), The Netherlands, 3F. Hoffmann-La Roche Ltd., Basel, Switzerland
OBJECTIVES: In economic theory economic surplus refers to two related quantities:
Consumer surplus (monetary gain obtained by consumers because they are able to
purchase a product for a price that is less than the highest price they would be
willing to pay) and producer surplus (amount that producers benefit by selling at a
market price that is higher than the least they would be willing to sell for). Applying
the theory to health care economic surplus could be translated as convenience
benefits which could be skimmed by patients, physicians or health care payers.
METHODS:Various areas of economic surplus were being screened and three areas
in Germany, the Netherlands and the UK were analysed: Caesarean births, emer-
gency room visits (nights or weekends) and response surplus. A targeted literature
search was being conducted to identify the costs. The economic surplus (conve-
nience value) was calculated. RESULTS: The economic surplus for non-medical
driven Caesarean births was calculated as the difference of a DRG (Diagnosis Re-
lated Groups) for a vaginal birth and a Caesarean birth in Germany and was equal
to € 828 per case. In the UK emergency visits during nights or weekends were
analysed. Standard HRG (Healthcare Resource Group) value for an emergency visit
was applied and the theoretical surplus was calculated applying a proxy-add-on
taken from the proportionally higher wages during premium times and was rang-
ing between € 94 and € 137 per case for nights shifts and weekends respectively. As
an example of response surplus IVF-treatments in the Netherlands were chosen
where it can be shown that there might be a patient surplus of up to € 4’096 per
saved IVF-treatment. CONCLUSIONS: The application of standard economic the-
ory confirms the availability of surplus skimming in health care and shows that
health care systems are indirectly accepting and paying for convenience.
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HEALTH CARE UTILIZATION RESEARCH IN GERMANY: CHARACTERIZATION OF
THE NORDBADEN DATABASE
Schlander M, Schwarz O
Institute for Innovation & Valuation in Health Care, Wiesbaden, Germany
OBJECTIVES: The Nordbaden Project was established in 2003 as a cross-sectional
analysis of the administrative prevalence, resource use, and direct medical costs
associated with attention-deficit/hyperactivity disorder (ADHD). Meanwhile, the
project has evolved into a longitudinal patient-centered study, allowing to follow
identified patients over prolonged periods of time and to study the impact of mod-
erators (e.g., coexisting conditions) and mediators (e.g., specialist involvement) on
the quality and cost of health care services provided. The database enables retro-
spective health care utilization studies based upon claims data of the Kassenaerztli-
che Vereinigung (KV) in Nordbaden (“Regierungsbezirk Karlsruhe”), an affluent region
in Southwestern Germany. METHODS: The database covers the complete regional
population enrolled in statutory health insurance (SHI; 2.2 million lives). Based
upon prospective data analysis plans, the vdek group of sick funds within SHI
(850,000 lives in year 2009) offers prescription data for the subsample of patients
insured by its member companies. Here, sociodemographic data of the study sam-
ple are compared to national averages (year 2009) to assess its representativeness.
RESULTS: The demographic structure (by age and gender) of the Nordbaden sam-
ple (including its vdek subgroup) compares well to the national population. How-
ever, regional population density is much higher (396/sqkm versus 229/sqkm in
2009), and GDP per capita (34,800€ versus 29,300€) as well as the rate of persons
insured by private sick funds (instead of SHI: 18.2% versus 14.6%) exceed the na-
tional average. There are also relatively more health care specialists in Nordbaden
(for example, 11,400 persons per mental health care specialist and 3,200 per psy-
chotherapist) compared to Germany (17,200 and 3,900, respectively), whereas the
relative number of general practitioners is somewhat lower (with 1,500 persons per
g.p. versus 1,400). CONCLUSIONS: The Nordbaden sample constitutes a well-char-
acterized study population. However, interpretation of observations should take
into account the well-documented differences between region and nation.
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THE OTC POLICY IN EYROPE AND GREECE
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OBJECTIVES: To analyses the policies implemented for the pricing, promotion and
classification of over-the-counter (OTC) drugs, in several European countries and to
compare them with those in Greece. METHODS: The study presents in detail the
structure of the prescription drug (Rx) and OTC market and the prevailing corre-
sponding policies in 23 European countries. The data used in the study were mainly
derived from the published literature and were synthesized and categorized with
emphasis on the classification process, pricing, reimbursement and promotion of
Rx and OTC. The above process was used to reveal and highlight commonalities
and differences between the countries. RESULTS: It was found that the great ma-
jority of European countries apply free pricing for OTC drugs and only few countries
choose state intervention. The 21 out of the 23 countries allow the OTC market to
self regulate through the mechanisms of the market and competition and the main
exclusion is Greece, which is one of the two countries, from those examined, which
the government regulates the prices of OTC drugs. This policy initially was in-
tended to protect consumers from excessive pricing and overconsumption of
widely used drugs but has opposite results. In terms of the content, the analysis
indicates that the positive and negative lists are wider in the case of Greece and the
OTC list is narrower compared with the remaining countries. CONCLUSIONS: In-
ternational experience indicates that the OTC list in Greece is narrower and heavily
regulated in terms of price relative to other countries. This may lead to opposite
results that those intended by budget holders. Careful expansion of the OTC list
along with release of their prices, may lead to savings for the public spending and
greater access to patients at reasonable cost and a patient level.
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OBJECTIVES: To estimate the economic impact of switching established prescrip-
tion drugs (Rx) to over-the-counter drugs (OTC), for different stakeholders (pa-
tients, social insurance funds, the national economy, physicians). METHODS: An
algorithm was constructed to estimate the percentage of drugs that could be trans-
ferred from the positive and the negative list to the OTC one, based on data ob-
tained from the OTC lists of 24 countries in Europe. In the algorithm, it was as-
sumed that a drug could be transferred in the OTC list in Greece if it was included
in the corresponding list of at least seven other European countries. Based on this
approach, it was calculated that 4.3% and 40% of drugs belong to the reimburse-
ment and negative list, respectfully, could be shifted to the OTC list. The economic
impact of the switch was estimated based on the reduction of medical visits, the
change of drug prices, the chance of copayments, the reduction in transportation
costs and the increase of patient productivity. The analysis was stochastic.
RESULTS: In the base case scenario, the total annual savings for the social funds is
estimated at 170€ million and the benefit for the economy at 78,96€ million. Pa-
tients are charged with extra 95€ million for drugs. It is estimated that the switch
reduces the number of medical visits by 1,8 million and saves 1,28 million days of
work. An increase of individual per capital expenditure by 9.4€ due to switch to OTC
drugs could benefit by 249€ million to the national economy. These results were
confirmed in two additional scenarios. CONCLUSIONS: The findings of this study
suggest that the Rx-to-OTC switch may reduce the health care costs of social se-
curity funds and may benefit the national economy overall, with some reasonable
extra costs incurred by patients on an individual basis.
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OBJECTIVES: Greece goes through a major economic crisis and a reform program,
in the context of which an aim is to cut by half drug spending within four years.
Expansion of the over-the-counter (OTC) drug list could contribute to the reduction
of public spending. Hence, a review was undertaken to investigate the implications
of expanding their use. METHODS: Relevant published studies examining the ef-
fect of using OTC drugs were identified with search in MEDLINE, EBSCO and
PUBMED. The literature search was based on the following terms: Over the counter,
OTC, drugs, prescription medicine, Rx, Non Rx, benefit, economic impact, self-care.
Studies were included based on the following criteria: peer-reviewed English-lan-
guage articles, published from 2000 and over, cited at least in 25 other articles. The
selected studies were divided into three groups based on the stakeholder for whom
the study had been conducted. RESULTS: For patients, the shift of drugs from
prescription to OTC status leads to increased access, greater utilization, reduced
traveling cost and physician payments, increases in productivity and drug expen-
diture. The switch reduces public spending on drugs and physician visits. However,
the expansion of the OTC list may in certain cases be associated with risks and
negative effects on health outcomes, if patients are not well informed regarding the
ways of responsible self-medication. Finally, the literature review revealed that
patients are more likely to prefer a, more expensive, prescription drug from a
cheaper but similar in effectiveness non-prescription one if both are available.
CONCLUSIONS: It is evident that the greater use of OTC drugs may improve access,
convenience, service, health outcomes and patient satisfaction and may reduce
the expenditures of social insurance, under certain well controlled and designed
circumstances. In particular the drugs need to be carefully selected and the pa-
tients and pharmacists well informed and trained on responsible self-medication.
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COST-EFFECTIVENESS IN HEALTH CARE PROGRAMS: A LITERATURE REVIEW
Vanhaute OA1, Annemans L2
1University Hospital Ghent, Belgium, Ghent, Belgium, 2Ghent University & Brussels University,
Ghent, Belgium
OBJECTIVES: Aging population, chronic conditions and financial constraints are
among the main challenges for our health care organization. Disease management
programs and multidisciplinary teams are often proposed as possible solutions
but, while cost effectiveness (CE) is well accepted and almost evident in the eval-
uation of drugs and technologies, it is not sure that it is also common use in the
implementation of new health care programs. METHODS: In December 2011 we
conducted a search for publications since 2000, in Pubmed, Cinahl, Econlit and
Biomed Central, with “care program” or “disease management program” or “reha-
bilitation program” as mesh terms. To identify in how many cases generic health-
related quality of life (HR-QoL) questionnaires were used, the search was extended
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with the terms “EQ-5D”, “SF-36”, “SF-12” and “SF-6D”. RESULTS: The initial search
revealed 5745 publications, 227 of which referring to the HR-QoL questionnaires, of
whom 209 were considered as relevant . Of these, 69 publications were proposed
study protocols in which 31 announced to evaluate CE as an outcome value.
Amongst the remaining 140 papers, 34 were reporting on a new technique, an
alternative questionnaire or on HR-QoL without referring to CE, and 33 were re-
porting on pharmacology or HTA. This results finally in 73 research reports regard-
ing care programs. In only 5 (7%) of them CE has been evaluated, in which 4 by
comparing direct costs and 1 by using QALY’s as outcome value. CONCLUSIONS:
While longitudinal care programs for chronically ill implicate the use of many
health care workers and labour cost is known to count heavily on the budget, CE is
until now, almost never evaluated. Although CE can obviously not be claimed to be
the single important criterion, it is a promising evolution to notice that many study
protocols in this field also aspire after this outcome value.
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EVALUATION OF REAL LIFE USE OF SUGAMMADEX FOR DECURARIZATION OF
NEUROMUSCULAR BLOCKADE IN SURGICAL INTERVENTIONS IN BELGIUM
Caekelbergh K, Lamotte M
IMS Health, Vilvoorde, Belgium
OBJECTIVES: Sugammadex is registered for decurarization of moderate/deep neu-
romuscular blockade induced by rocuronium or vecuronium. The advantages com-
pared to the well-known decurarization drugs like neostigmine is that undesirable
side-effects (bradycardia-bronchoconstriction-hypersalivation-nausea-vomiting)
are avoided and deeper levels of blockade can be reversed. In Belgium its reim-
bursement is restricted to certain conditions (impossible intubation or rapid decu-
rarization of deep blockade when medically required or rapid decurarizaton mod-
erate blockade in patients with obstructions (stomach/bowel, bile duct, urinary
tract) or when administration of neostigmine is contra-indicated). The objective of
this study was to evaluate Belgian real-life use of sugammadex one year after
reimbursement was granted.METHODS: The medical records of 330 adult patients
being treated with sugammadex during the first half year of 2011 (6 hospitals se-
lecting 55 consecutive patients) were retrospectively reviewed. Data collection in-
cluded baseline patient-characteristics, hospital-, surgery- and sugammadex-re-
lated info. In addition, a 2-round expert-panel among 12 physicians was organized.
RESULTS: Based on the expert-panel (in combination with published data), it was
estimated that in Belgium rocuronium is used in about 58,100 surgical interven-
tions per year. Reversal with sugammadex is performed in 21.5% of them. Mean age
of the patients using sugammadex was 54 years (/ 17 SD), 45% of the patients
belonged to ASA (American Society of Anesthesiologists) category I-II (healthy-
mild systemic disease), 33% to categoryIII, 84% had co-morbidities. Sugammadex
is mainly used after gastroenterological surgery (53%; high contribution of bariat-
ric-surgery), followed by gynaecological interventions (12%), estimates confirmed
by the expert-panel. According to the experts, in 29% of the patients reversal with
sugammadex was used outside the reimbursement conditions. CONCLUSIONS:
The study confirms that, in Belgium, sugammadex is used when medically needed,
a substantial part being used outside the reimbursement conditions.
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A REIMBURSEMENT METHOD FOR THE PUBLIC HEALTH CENTERS IN GREECE
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OBJECTIVES: To propose a prospective payment method for the public Health Cen-
ters (HC) in Greece, based on the reimbursement method of Ambulatory Patient
Groups (APG). METHODS: In the absence of electronic patient records, imple-
mented International Classification of Diseases and Current Procedural Terminol-
ogy coding systems, an updated costing system and given that HC in Greece pro-
vide a quite low bundle of services the methodology of the study was accordingly
adjusted. The services provided by the HC were grouped and classified in a few
distinct groups and evaluated by a Delphi panel according to their usability, coher-
ence and technology and labor resource use. According to each groups resource
use, a corresponding labor and technology weight was estimated. An expert panel
estimated the percentage contribution of labor and technology cost in the payment
of each group. The average cost of visit in the HC was used as a base rate. A
mathematical model employed these parameters and provided an estimation of
each group’s payment. Model’s results and parameters were evaluated and ad-
justed to a second expert panel recommendations. APGs’ packaging and discount-
ing techniques were applied. RESULTS: Sixteen groups were created and priced as
follows: Emergency Management (102.6€), Acute Case Management (64.7€), Follow up/
Revisit for an urgent/emergency problem (29.5€), Complete Health Evaluation (48.1€),
Partial Health Evaluation (39.6€), Regular consultation of healthy individual (34.9€),
Laboratory tests (100.8€), Prescription/simple repetition (4.7€), Prescription of drugs/
laboratory tests with Basic medical exam (18.7€), Simple diagnostic/therapeutic pro-
cedure (26.9€), Complex diagnostic/therapeutic procedure (57.6€), Immunization
(23.5€), Primary Prevention/Health education (24.7€), Complex preventive procedure
(39.8€), Physical medicine/Rehabilitation/Counseling/Psychotherapy/Social support
consultation (29.1€), Administrative procedure (12.8€). CONCLUSIONS: Despite the
limitation imposed by the health system’s infrastructure, the current study is es-
timated that can provide a viable reimbursement method and a starting point for
the development of a more detailed method in the future.
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OBJECTIVES: Describe and analyze recent changes in the French drug market ac-
cess in which a dramatic shift in practice is undergoing and impacted by two laws
entered into force in December 2011. METHODS: Literature review was performed
to provide core understanding of the current and future trends in French drug
market access to anticipate its impact for pharmaceutical industry. RESULTS: Con-
dition severity used to be main driver of reimbursement level is now replaced by
drug efficacy criterion. Moreover, the effect size requested for acknowledging drug
innovation has substantially increased. Perceived evidence might also be more
important than actual evidence. Currently, the French National Authority (HAS) is
working on a new therapeutic index that will drive the pricing and reimbursement.
Comparative evidence and real world data are pointed as critical, conditioning
marketing authorization, and will be increasingly requested at the light of the new
drug safety law n.2011-2012. Moreover, within this new legal framework there is a
reinforcement of the regulation about conflicts of interest, a much closed regula-
tion of off-label prescription and early entry of drugs as well as a wide promotion of
generic drugs. The new social security funding law n.2011-1906 pursues the cost
containment measures to control health insurance expenses. This law includes the
Economic and Public Health Assessment Committee (CEESP) in the social security
code. CEESP, that will operate independently of the Transparency Committee, is in
charge of health economics evaluation to determine the most efficient therapeutic
strategies and edit recommendations for decision makers. CONCLUSIONS: French
drug market access will be more and more driven by comparative cost-effective-
ness data and post-marketing studies. Companies will need to anticipate these
requirements during the drug development. However in France, there exists little
or no culture of using health economics for decision making and rather resistance
to it.
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OBJECTIVES: Pricing regulation in Japan is thought to be conservative, however
over the last years, an acceleration of pricing regulation changes has occurred. We
propose to review the dramatic pricing regulation changes that have occurred
especially in 2012. METHODS: Collection and analyses of changes have been per-
formed through literature review of public sources and key opinion leader’s
interviews. RESULTS: One of the main changes concerns pediatric indication that
will now induce premium price for drugs from 5% to 20%, conditional to substantial
efforts from pharmaceutical companies, including studies in Japan and pediatric
formulations. Then, usual cost plus calculation, using the last year as reference for
production, labor, distribution costs etc., will now use the average of the previous 3
years to minimize inflation. International reference pricing have been reviewed to
minimize the cost impact on NHS. As for generics, although they doubled in vol-
ume and value over the last 10 years, they progress slowly: in 2011, generic market
was 23% in volume and 9.5% in value. To counter this, doctors are now eligible for
generic prescription incentive and high co-payment on brand appears to be the
way forward to support generic uptake. Prescription form has been reviewed to
ease request for generic substitution. Generics are priced between 30% discount
down to 46% discount at the maximum. In parallel, enantiomer drugs will now be
discounted by 20% over racemates. This will put them close to generic price (30%
discount). However, opportunities for re-pricing up products were closed to pre-
vent orphan drugs from expanding indication market size and later revenue. Fi-
nally, high drug costs will be excluded from reimbursement through a process
based on drug price distribution to secure convergence toward mean price.
CONCLUSIONS:Despite apparent peace and resistance to changes, Japan market is
also undergoing dramatic changes.
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IS THERE AN OVERUSE OF COMPUTED TOMOGRAPHY (CT) SCANNING OF
PATIENTS IN UNITED STATES HOSPITALS? A REVIEW OF THE EVIDENCE
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OBJECTIVES: Radiologists claim that performing two or more CT scans in succes-
sion is rarely necessary, yet the practice of multiple CT scanning during the same
visit has continued in recent years. The objective of this study is to review the
evidence and identify factors contributing to this practice. METHODS: The retro-
spective study included patients from the US Medicare 2009 hospital database.
Over 6 million outpatient claims with the following information were extracted:
patient demographics, hospital characteristics, CT scans hospital charges and
body parts associated with CT scan administration. Multi-level logistic mixed ef-
fects regression was conducted to identify significant factors associated with the
overuse of CT scans among US hospitals. RESULTS: There were 690,643 Medicare
patients that received multiple CT scans during a hospital outpatient visit in 2009.
More than 664 hospitals that administered at least two scans on more than 30% of
their Medicare outpatients. The national average was 5.4%. The figures show wide
variation among states as well, from about 5% in Maryland to almost 23% in Okla-
homa. After multivariable adjustment, female patients had a lower incidence rate
of CT scan overuse (odds ratio, 0.850; 95% CI, 0.847 to 0.851, p0.0001). Rural hos-
pitals tend to practice more CT scan overuse (odds ratio, 1.835; 95% CI, 1.670 to
2.016, p0.0001) than urban hospitals. Hospital charged patient costs of CT scans
also tend to vary across regions. CONCLUSIONS: There is strong statistical evi-
dence that US hospitals practice of CT scan overuse continued in 2009 based on the
Medicare outpatient population. While the study is subject to limitations, it cor-
roborates with previous policy studies that hospitals can and should do more to
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